We are live on ! Find out more

ProMIS Neurosciences

PMN

Market cap $36.3M

4.05 USD

-0.11

2.64%

At close Updated Nov 9, 4:00 PM EST

Pre-market

After hours

4.00

-0.05

1.23%

1 day

-2.64%

5 days

23.1%

1 month

-57.86%

3 months

-72.49%

6 months

-62.08%

Year to date

-43.28%

1 year

-58.33%

5 years

-98.25%

10 years

-98.25%

About: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Employees: 11

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

ProMIS Neurosciences to Participate in Upcoming Conferences in November

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside chats will be delivered by Neil Warma, President and Chief Executive Officer. Members of the Company's leadership team will be available for one-on-one meetings at the conferences.

ProMIS Neurosciences to Participate in Upcoming Conferences in November

Zacks Investment Research

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026

Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the third quarter ended September 30, 2026, and provide corporate updates on November 12, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m.

ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026

Zacks Investment Research

Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade

The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade

ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

Former senior Biogen and Roche executive brings deep experience across Alzheimer's clinical development, launch readiness, commercialization and global medical strategy

ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Promis Neurosciences Q2 Earnings Call Highlights

Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.

Promis Neurosciences Q2 Earnings Call Highlights

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data

Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer's disease and early Alzheimer's disease.

Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data

See News Rankings

Price charts implemented using Lightweight Charts™